Stock Financial Ratios


ETRM / EnteroMedics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.05
Volume1,061,600.00
Market Cap ($M)19.42
Enterprise Value ($M)4.18
Book Value ($M)2.94
Book Value / Share4.72
Price / Book0.38
NCAV ($M)2.98
NCAV / Share4.78
Price / NCAV0.38
Income Statement (mra) ($M)
Revenue0.79
EBITDA-22.80
Net Income-23.36
Balance Sheet (mrq) ($M)
Cash & Equivalents23.43
Cash / Share37.65
Assets55.18
Liabilities4.14
Quick Ratio0.97
Current Ratio1.41
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-7.95
Return on Assets (ROA)-3.32
Return on Equity (ROE)-7.95
Identifiers and Descriptors
CUSIP29365M208
Central Index Key (CIK)1371217
Industry Groups
SIC 3845 - Electromedical and Electrotherapeutic Apparatus
Other Related CUSIPS
29365M955
29365M307
29365M908
29365M505
29365M905
29365M125
29365M958
Share Statistics
Common Shares Outstanding (M)21.72
Scoring Models
Piotroski F Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Cash And Equivalents Per Share37.65
Liabilities Per Share6.64
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Assets Per Share88.66
Property Plant And Equipment Per Share0.31
Retained Earnings Per Share-522.37
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Goodwill Per Share10.28
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Liabilities And Stock Equity Per Share88.66
Property Plant And Equipment Net Per Share0.31
Assets Current Per Share41.14
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Inventory Per Share2.55
Equity Per Share82.01
Treasury Stock Per Share0.00
Assets Other Current Per Share0.00
Assets Other Non Current Per Share1.84
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accounts Receivable Per Share0.54
Additional Paid In Capital Per Share604.18
Liabilities Current Per Share6.64
Cash Per Share37.65
Inventory Work In Progress Per Share0.00

Stock Research Report

EnteroMedics is a medical device company focused on the development and commercialization of technology to treat obesity and metabolic diseases.

The vBloc®System, its initial product, is a U.S. Food and Drug Administration (FDA)-approved pacemaker-like device that delivers vBloc® Neurometabolic Therapy (vBloc Therapy) to help patients feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The company's therapy limits the expansion of the stomach, helps control hunger sensations between meals, reduces the frequency and intensity of stomach contractions and produces a feeling of early and prolonged fullness. The company believe the vBloc System offers obese patients a minimally-invasive treatment that can result in significant, durable and sustained weight loss. The company believe that its vBloc System allows bariatric surgeons to offer a new option to obese patients who are concerned about the risks and complications associated with currently availabl...

Click for full article

Related News Stories

Zacks.com highlights: Avon Products, Altria Group, EnteroMedics, Macquarie Infrastructure and Sibanye Gold

2017-11-02 zacks
Chicago, IL – November 2, 2017 - Stocks in this week’s article include: Avon Products Inc. (AVP - Free Report) , Altria Group (MO - Free Report) , EnteroMedics Inc. (RSLS - Free Report) , Macquarie Infrastructure Company (MIC - Free Report) and Sibanye Gold Limited (SBGL - Free Report) . (122-1)

Rising P/E: An Overlooked Way to Reach 5 Winning Stocks

2017-11-01 zacks
Picking bargain stocks with a low price-to-earnings (P/E) ratio is a common practice. The idea is that the lower the P/E, the higher will be the value of the stock. Investors believe that a stock’s current market price is not equivalent to its higher earnings and therefore has room to run. (50-1)

athenahealth (ATHN) Beats Earnings, Misses Revenues in Q3

2017-10-20 zacks
athenahealth Inc. (ATHN - Free Report) reported adjusted earnings of 56 cents per share in the third quarter of fiscal 2017, steering past the Zacks Consensus Estimate of 50 cents. However, earnings lagged the year-ago quarter’s 60 cents. (95-1)

Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues

2017-10-20 zacks
Intuitive Surgical Inc. (ISRG - Free Report) posted adjusted earnings of $2.77 per share in the third quarter of 2017, crushing the Zacks Consensus Estimate of $1.97 on stellar revenue growth. Also, the figure improved 34.5% on a year-over-year basis. Interestingly, over the past four quarters, the company beat estimates at an average of 7.8%. (81-0)

EnteroMedics Announces New Employee Inducement Option Grants

2017-10-12 prnewswire
ST. PAUL, Minn., Oct. 12, 2017 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Compensation Committee of the Board of Directors of EnteroMedics granted stock options covering an aggregate of 1,255,000 shares of EnteroMedics common stock to 51 persons newly employed by EnteroMedics as a result of the ReShape Medical, Inc. (28-0)

CUSIP: 29365M208